- CITATIONS: 4
|Application ||WB, IHC-P, FC, E|
|Calculated MW||56124 Da|
|Antigen Region||38-68 aa|
|Other Names||Serine/threonine-protein kinase receptor R3, SKR3, Activin receptor-like kinase 1, ALK-1, TGF-B superfamily receptor type I, TSR-I, ACVRL1, ACVRLK1, ALK1|
|Target/Specificity||This ACVRL1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 38-68 amino acids from the N-terminal region of human ACVRL1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||ACVRL1 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Type I receptor for TGF-beta family ligands BMP9/GDF2 and BMP10 and important regulator of normal blood vessel development. On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. May bind activin as well.|
|Cellular Location||Membrane; Single-pass type I membrane protein|
Provided below are standard protocols that you may find useful for product applications.
ACVRL1 is a type I cell-surface receptor for the TGF-beta superfamily of ligands. It shares with other type I receptors a high degree of similarity in serine-threonine kinase subdomains, a glycine- and serine-rich region (called the GS domain) preceding the kinase domain, and a short C-terminal tail. This protein, sometimes termed ALK1, shares similar domain structures with other closely related ALK or activin receptor-like kinase proteins that form a subfamily of receptor serine/threonine kinases. Mutations in this gene are associated with hemorrhagic telangiectasia type 2, also known as Rendu-Osler-Weber syndrome 2.
Strausberg, R.L., et al., Proc. Natl. Acad. Sci. U.S.A. 99(26):16899-16903 (2002).
Berg, J.N., et al., Am. J. Hum. Genet. 61(1):60-67 (1997).
Johnson, D.W., et al., Nat. Genet. 13(2):189-195 (1996).
ten Dijke, P., et al., Oncogene 8(10):2879-2887 (1993).
Attisano, L., et al., Cell 75(4):671-680 (1993).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.